Sharon Worcester, MA

News

FDA Approves Avastin Biosimilar Agent, Jobevne

Author:: Sharon Worcester, MA

Publish date: April 15, 2025

Approval of Jobevne for IV use across multiple cancer types based on data illustrating its clinical similarities to Avastin.

News

FDA OKs First-line Nivolumab + Ipilimumab in Advanced HCC

Author:: Sharon Worcester, MA

Publish date: April 15, 2025

Decision comes after nivolumab displayed efficacy to treat advanced HCC in a trial of > 650 patients.

News

Assay Shows Promise for Early-Stage Melanoma Risk Assessment Beyond SNLB

Author:: Sharon Worcester, MA

Publish date: April 8, 2025

The noninvasive Merlin assay may help identify recurrence risk in early-stage melanoma patients who skip sentinel lymph node biopsy.

News

FDA Approves Pluvicto for Earlier Use in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Author:: Sharon Worcester, MA

Publish date: April 1, 2025

The radioligand therapeutic agent was previously approved for patients who have already received ARPI therapy and taxane-based chemotherapy.

News

New Cancer Vaccines on the Horizon: Renewed Hope or Hype?

Author:: Sharon Worcester, MA

Publish date: December 6, 2024

Following a string of disappointments over the past decade, recent advances in the immunotherapy space are bringing renewed hope for progress.

News

FDA Approves Bizengri for NSCLC and Pancreatic Cancers Harboring NRG1 Gene Fusion

Author:: Sharon Worcester, MA

Publish date: December 5, 2024

The targeted therapy is the first approved by the FDA for patients with NSCLC or pancreatic adenocarcinoma harboring an NRG1 gene fusion.

News

FDA Approves Obe-cel, a Novel CD19 CAR T Product for ALL

Author:: Sharon Worcester, MA

Publish date: November 11, 2024

Obe-cel has been shown to improve response rates and survival, particularly in adult patients with low leukemia burden.

News

Cannabis in Cancer: What Oncologists and Patients Should Know

Author:: Sharon Worcester, MA

Publish date: October 23, 2024

Access to and use of cannabis alongside cancer care have outpaced the science on evidence-based indications, according to an ASCO expert panel.

News

Gotistobart Trial for NSCLC on Partial Clinical Hold

Author:: Sharon Worcester, MA

Publish date: October 23, 2024

The trial assessed the safety and efficacy of the agent vs docetaxel as monotherapy in patients with metastatic NSCLC that progressed des...

News

ACS: Breast Cancer Incidence Rising, Mortality Disparities Persist

Author:: Sharon Worcester, MA

Publish date: October 9, 2024

Deaths from breast cancer, however, declined from 1989 to 2022, with an overall drop of 44%.

News

Isatuximab Quadruplet Approval Could Change the Landscape for Treating Myeloma

Author:: Sharon Worcester, MA

Publish date: October 7, 2024

Findings of phase 3 IMROZ trial demonstrated the efficacy of Isa-VRd, a four-drug combo, in treating patients newly diagnosed with myeloma.

News

MM: First CAR T-Cell Therapy to Exhibit OS Benefit

Author:: Sharon Worcester, MA

Publish date: October 3, 2024

CARTITUDE-4 study update indicated that CAR T-cell therapy improves overall survival in relapsed/refractory multiple myeloma.

News

FDA Okays Osimertinib After CRT in Locally Advanced, Unresectable NSCLC

Author:: Sharon Worcester, MA

Publish date: September 27, 2024

The drug was approved for patients whose disease has not progressed during or after concurrent or sequential platinum-based chemoradiation therapy....

News

AACR Cancer Progress Report: Big Strides and Big Gaps

Author:: Sharon Worcester, MA

Publish date: September 26, 2024

The report focused on strides made in cancer care, prevention, and early detection and highlighted areas where more research and attention are warr...

News

FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer Indications

Author:: Sharon Worcester, MA

Publish date: September 17, 2024

The drug combo was the first programmed death–ligand 1 inhibitor to gain approval for subcutaneous administration.